The study was conducted in Australia, in 2007 and reported in The British Medical Journal in Dec 2008. Sharon Choo of the Royal Children’s Hospital in Melbourne reported that during 2007 more than 380,000 doses of the vaccine had been administered in schools in Victoria and South Australia under the Australian immunization program. Choo and colleagues noted some components of Merck’s treatment — such as aluminum salts and yeast — have been associated with allergic reactions. In the British Medical Journal article, published in late 2008, she and her colleges are quoted as saying, “Our clinical recommendation is that females with suspected hypersensitivity to the quadrivalent vaccine should be evaluated before receiving more doses, and any challenges with the same vaccine should be carried out in a supervised setting.”